PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Inclusion Criteria: Patients eligible for inclusion in this study had to meet all of the following criteria: * Patient must have had at least one prior line of therapy for their disease and must not be beyond 4th progression/relapse of disease (5 maximum prior lines). * Patient has a pathology confirmed diagnosis of a solid tumor or lymphoma listed in the section "condition". Patients must have measurable disease as per appropriate guidelines (Solid Tumors by RECIST 1.1 and Diffuse Large B-cell Lymphoma by Revised Response Criteria for Malignant Lymphoma - Cheson et al 2007). Exclusion Criteria: Patients eligible for this study must not meet any of the following criteria: * History of severe hypersensitivity reactions to other monoclonal antibodies. * Impaired cardiac function or clinically significant cardiac disease. * Active, known or suspected autoimmune disease or a documented history of autoimmune disease within three years prior to screening with a few exceptions as per protocol. * Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded. * Patient with second primary malignancy within \< 3 years of first dose of study treatment. * Prior immunotherapy treatment with PD-1, PD-L1, CTLA-4, or LAG-3 antibodies.